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Purpose: Application of pyrosequencing technology (pyrosequencing) detec-
tion of resistance genes of Mycobacterium tuberculosis (rpoB and gyrA) mu-
tation characteristics, evaluation of its clinical application, created by
pyrosequencing method on drug-resistance gene mutations of Mycobacte-
rium tuberculosis detection method.
Methods: Through the BACTEC-960 rapid culture and using the pyrosequenc-
ing technology, about 110 cases of tuberculosis drug resistance, analyzes the
characteristics of gene mutation, and the results were compared with con-
ventional susceptibility, pyrosequencing sensitivity is 96%.
Results: 110 strains of Mycobacterium tuberculosis resistance in the rpoB
gene of 57 strains of drug-resistant strains, the most common mutation
and mutant forms of respectively 531 TCG mutation for TTG,
Conclusions: Pyrosequencing technology is a high throughput and high per-
formance method in detecting mutation resistance in Mycobacterium
tuberculosis.
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Purpose: QuantiFERON-TB Gold In-Tube (QFT-IT) Test is an interferon
gamma release assay for diagnosis of latent tuberculosis infection (LTBI)
with the cutoff point of 0.35 IU/ml. This study is aimed to evaluate
how the cutoff point of 0.7 IU/ml for QFT-IT could impact the LTBI
program.
Methods: Contacts of TB who were born before Jan 1, 1986, received both
tuberculin skin test (TST) and QFT-IT in a pilot program conducted during
2010 to 2012 at seven townships in Taiwan. LTBI treatment was provided
to the contacts that had TST induration  10 mm and QFT-IT  0.35 (dou-
ble-positive). All contacts were cross-linked to national web-based registry
in Mar, 2014 to identify if the contact developed active TB.
Results: A total of 2203 contacts completed both TST and QFT-IT and 414
(18.8%) were double-positive. Figure reveals that double-positive and QFT-
IT positivity increases with age while TST positivity peaks at the age-group
of 35e44 years and declines afterwards. Among 414 double-positive con-
tacts, 245 (59%) started LTBI treatment and one developed active TB during
the therapy. Of the 169 contacts never receiving treatment, 5 (2.94%)developed active TB and 4 of them developed disease beyond contact inves-
tigation period. The NNTwas 42 persons to prevent one TB case. By using the
cutoff point of 0.7 IU/ml for QFT-IT, the cases needed to receive therapy
decreased to 335 with a 19% reduction and the NNT was 43 persons. Howev-
er, one extra patient developed TB fell into the category of not necessary for
LTBI treatment.
Conclusions: Further expansion of LTBI program into elderly needs more
contingent planning. Diagnosis of LTBI with double-positive of TST 10
mm and QFT-GIT 0.7 could reduce the number needed to receive therapy
with modest NNT, however, not all contact can expect to avoid active TB
completely.
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Purpose: Current WHO guideline suggested human immunodeficiency vi-
rus (HIV) infected persons to receive isoniazid preventive therapy (IPT)
for reducing risk of active TB. However, TB incidence had declined after
Figure Age Specific Positivity Based on Results of Tuberculin Skin Test or
QuantiFERON-TB Gold In-Tube Test by Different Cutoff Points
